- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04532203
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
October 22, 2020 updated by: He Huang, Zhejiang University
Clinical Trial for the Safety and Efficacy of CAR-T Cells Therapy for Patients With the Central Nervous System Involvement of Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia or B-cell Non-Hodgkin's Lymphoma
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
This is a single arm, open-label, single-center study.
This study is indicated for relapsed or refractory central nervous system CD19+ B-cell hematological malignancies, including acute lymphoblastic leukemia and B-cell non-Hodgkin's lymphoma.
The selections of dose levels and the numberof subjects are based on clinical trialsof similar foreign products.
Two groups of patients will be enrolled, 36 in eachgroup.
Primary objective is to explore the safety, main consideration is dose-related safety.
Study Type
Interventional
Enrollment (Anticipated)
72
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The First Affiliated Hospital,College of Medicine, Zhejiang University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 75 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Inclusion criteria only for B-ALL:
- Male or female aged 3-70 years;
- Histologically confirmed diagnosis of B-ALL per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphoblastic Leukemia (2016.v1);
Relapsed or refractory CD19+ B-ALL (meeting one of the followingconditions):
- CR not achieved after standardized chemotherapy;
- CR achieved following the first induction, but CR duration isless than 12 months;
- Ineffectively after first or multiple remedial treatments;
- 2 or more relapses;
- The number of primordial cells (lymphoblast and prolymphocyte)in bone marrow is>5% (by morphology), and/or >1% (by flowcytometry);
- Philadelphia-chromosome-negative (Ph-) patients; or Philadelphia-chromosome-positive (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI treatments;
Inclusion criteria only for B-NHL:
- Male or female aged 18-75 years;
- Histologically confirmed diagnosis of DLBCL (NOS), FL, DLBCL transformed from CLL/SLL, PMBCL, and HGBCL per the WHOClassification Criteria for Lymphoma (2016);
Relapsed or refractory B-NHL (meeting one of the followingconditions):
- No response or relapse after second-line or abovechemotherapy regimens;
- Primary drug resistance;
- Relapse after auto-HSCT;
- At least one assessable tumor lesion per Lugano 2014 criteria;
Common inclusion criteria for B-ALL and B-NHL:
- Highly suspected or confirmed central nervous system involvement of hematological malignancies;
- Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal, creatinine ≤ 176.8 umol/L;
- Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;
- No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;
- Estimated survival time ≥ 3 months;
- ECOG performance status 0 to 2;
- Patients or their legal guardians volunteer to participate in the study and sign the informed consent.
Exclusion Criteria:
Subjects with any of the following exclusion criteria were not eligible for this trial:
- History of craniocerebral trauma, conscious disturbance,epilepsy,cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;
- Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
- Pregnant (or lactating) women;
- Patients with severe active infections (excluding simple urinarytractinfectionand bacterial pharyngitis);
- Active infection of hepatitis B virus or hepatitis C virus;
- Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving inhaled steroids;
- Previously treated with any CAR-T cell product or other genetically-modified T cell therapies;
- Creatinine>2.5mg/dl, or ALT / AST > 3 times of normal amounts,orbilirubin>2.0 mg/dl;
- Other uncontrolled diseases that were not suitable for this trial;
- Patients with HIV infection;
- Any situations that the investigator believes may increase the risk ofpatients or interfere with the results of study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Administration of CAR T-cells
Dose escalation follows the standard 3+3 doseescalation design.
A total of 3 dose levels are set for subjects.
|
Surgical catheter placement into the fourth ventricle of the brain
Each subject receive CAR T-cells by intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity (DLT)
Time Frame: Baseline up to 28 days after CAR T-cells infusion
|
Adverse events assessed according to NCI-CTCAE v5.0 criteria
|
Baseline up to 28 days after CAR T-cells infusion
|
Incidence of treatment-emergent adverse events (TEAEs)
Time Frame: Up to 2 years after CAR T-cells infusion
|
Incidence of treatment-emergent adverse events [Safety and Tolerability]
|
Up to 2 years after CAR T-cells infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
B-cell acute lymphocytic leukemia(B-ALL), Overall response rate (ORR)
Time Frame: At Month 1, 3, 6, 12, 18 and 24
|
Assessment of ORR (ORR = CR + CRi) at Month 6, 12, 18 and 24
|
At Month 1, 3, 6, 12, 18 and 24
|
B-ALL, Overall survival (OS)
Time Frame: Up to 2 years after CAR-T cells infusion
|
From the first infusion of CAR-T cells to death or the last visit
|
Up to 2 years after CAR-T cells infusion
|
B-ALL, Event-free survival (EFS)
Time Frame: Up to 2 years after CAR-T cells infusion
|
From the first infusion of CAR-T cells to the occurrence of any event, including death, relapse orgene relapse, disease progression (any one occurs first), and the last visit
|
Up to 2 years after CAR-T cells infusion
|
B cell non-hodgkin's lymphoma (B-NHL), Overall response rate (ORR)
Time Frame: At Week 4, 12, and Month 6, 12, 18, 24
|
Assessment of ORR (ORR = CR + PR) per Lugano 2014 criteria
|
At Week 4, 12, and Month 6, 12, 18, 24
|
B-NHL, disease control rate (DCR)
Time Frame: At Week 12 and Month 6, 12, 18, 24
|
Assessment of DCR (DCR=CR+PR+SD) per Lugano 2014 criteria
|
At Week 12 and Month 6, 12, 18, 24
|
Quality of life
Time Frame: At Baseline, Month 1, 3, 6, 9 and 12
|
Assessment of Quality of life using Research and Treatment of Cancer QOL Core Questionnaire 30 (EORTC QLQ-30) at Baseline, Month 1, 3, 6, 9 and 12
|
At Baseline, Month 1, 3, 6, 9 and 12
|
IADL score
Time Frame: At Baseline, Month 1, 3, 6, 9 and 12
|
Assessment of IADL score at Baseline, Month 1, 3, 6, 9 and 12
|
At Baseline, Month 1, 3, 6, 9 and 12
|
ADL score
Time Frame: At Baseline, Month 1, 3, 6, 9 and 12
|
Assessment of ADL score at Baseline, Month 1, 3, 6, 9 and 12
|
At Baseline, Month 1, 3, 6, 9 and 12
|
HADS score
Time Frame: At Baseline, Month 1, 3, 6, 9 and 12
|
Assessment of Hospital Anxiety and Depression Scale (HADS) score at Baseline, Month 1, 3, 6, 9 and 12
|
At Baseline, Month 1, 3, 6, 9 and 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2020
Primary Completion (Anticipated)
November 1, 2023
Study Completion (Anticipated)
November 1, 2026
Study Registration Dates
First Submitted
August 20, 2020
First Submitted That Met QC Criteria
August 25, 2020
First Posted (Actual)
August 31, 2020
Study Record Updates
Last Update Posted (Actual)
October 26, 2020
Last Update Submitted That Met QC Criteria
October 22, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CNSL-ZhejiangU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States
-
Immune DesignMerck Sharp & Dohme LLCTerminatedFollicular Low Grade Non-Hodgkin's Lymphoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
SCRI Development Innovations, LLCBiogenCompleted
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
Clinical Trials on Ommaya Reservoir
-
Mayo ClinicNational Cancer Institute (NCI)Recruiting
-
Fudan UniversityRecruitingHER2-negative Breast Cancer | Leptomeningeal MetastasisChina
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)TerminatedBrain and Central Nervous System TumorsUnited States
-
University of California, San FranciscoBill and Melinda Gates Foundation; Medical Research Council, South Africa; Ibis... and other collaboratorsWithdrawn
-
Mayo ClinicRecruitingRecurrent GlioblastomaUnited States
-
University of California, San FranciscoMakerere University; Infectious Diseases Research Collaboration, Uganda; Intellectual...Terminated
-
Yonsei UniversityRecruitingHeart Failure, Diastolic | Heart Failure, Preserved Ejection FractionKorea, Republic of
-
The University of Texas Health Science Center,...CompletedMalignant Neoplasm of Fourth Ventricle of Brain | Brain Tumor, RecurrentUnited States
-
Cedars-Sinai Medical CenterSientra, Inc.CompletedBreast Cancer | Hereditary Breast and Ovarian Cancer Syndrome | Breast Implant; ComplicationsUnited States
-
Hospital Universitari de BellvitgeCompletedLow Rectal Adenocarcinoma